AKAP 12 Activators
AKAP12 activators encompass a diverse group of chemicals that modulate cellular signaling pathways, particularly those related to cyclic AMP (cAMP) and protein kinase A (PKA). The primary mode of action for these activators involves either increasing intracellular cAMP levels or directly influencing PKA activity. Increased cAMP levels, achieved through the inhibition of phosphodiesterases or the activation of adenylyl cyclase, lead to the activation of PKA. This kinase is a crucial component of the signaling cascade, as it interacts directly with AKAP12, a scaffold protein that coordinates the localization and function of PKA within the cell. By modulating the activity of PKA, these chemicals indirectly influence the function and activation state of AKAP12.
The interaction between AKAP12 and PKA is pivotal in several cellular processes, including the regulation of signal transduction pathways. The chemicals classified as AKAP12 activators, therefore, play a critical role in modulating this interaction. They achieve this either by altering the levels of cAMP, which is a secondary messenger crucial in the PKA activation pathway, or by affecting the activity of PKA itself. This modulation can lead to changes in the spatial and temporal dynamics of PKA signaling within the cell, thereby indirectly influencing the activity of AKAP12.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin is an activator of adenylyl cyclase, increasing cAMP levels. Elevated cAMP can enhance PKA activity, which is known to interact with AKAP12, potentially leading to its activation. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-specific inhibitor of phosphodiesterases, which leads to increased cAMP levels by preventing its breakdown. This indirectly can boost PKA activity and could influence AKAP12 activation. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Cilostamide is a selective inhibitor of phosphodiesterase 3 (PDE3), leading to increased cAMP levels and thereby potentially enhancing PKA activity, which can interact with AKAP12. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase 4 (PDE4), increasing cAMP levels in cells. This increase in cAMP can indirectly activate AKAP12 by enhancing PKA activity. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine activates adrenergic receptors, leading to increased cAMP levels via adenylyl cyclase activation. This can enhance PKA activity, potentially influencing AKAP12. | ||||||
Adenosine 3′,5′-cyclic Monophosphate, N6-Benzoyl-, Sodium Salt | 30275-80-0 | sc-300167 | 10 µmol | $324.00 | 1 | |
6-Bnz-cAMP is a cAMP analog that activates PKA. By activating PKA, it could influence the activity of AKAP12, which is known to interact with PKA. | ||||||
Sp-cAMPS | 93602-66-5 | sc-201571 | 1 mg | $97.00 | 3 | |
Sp-cAMPS is a cAMP analog resistant to degradation by phosphodiesterases. It can activate PKA and potentially influence AKAP12 activity due to the interaction between PKA and AKAP12. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
Dibutyryl cAMP is a membrane-permeable analog of cAMP. By increasing intracellular cAMP levels, it can activate PKA, which may influence AKAP12 activation. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
Vinpocetine is an inhibitor of PDE1, leading to increased cAMP levels and thereby potentially influencing PKA activity and AKAP12 activation. | ||||||